These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33631080)

  • 1. Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine.
    Watle SV; Næss LM; Tunheim G; Caugant DA; Wisløff T
    Hum Vaccin Immunother; 2021 Aug; 17(8):2777-2787. PubMed ID: 33631080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.
    Si S; Zomer E; Fletcher S; Lee J; Liew D
    Vaccine; 2019 Aug; 37(35):5009-5015. PubMed ID: 31301916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation on meningococcal vaccination strategies among children under nine years of age in Zhejiang province, China.
    Shen J; Ji C; Luo X; Hu Y
    PLoS One; 2024; 19(9):e0310274. PubMed ID: 39250492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness Comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada.
    De Wals P; Zhou Z
    Pediatr Infect Dis J; 2017 Jul; 36(7):e203-e207. PubMed ID: 28027288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
    Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
    Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.
    Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL
    Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of vaccination strategies against meningococcal disease for children under nine years of age in China.
    Zhang H; Zhang H; Fang H
    Hum Vaccin Immunother; 2024 Dec; 20(1):2313872. PubMed ID: 38348600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study.
    Ohm M; Hahné SJM; van der Ende A; Sanders EAM; Berbers GAM; Ruijs WLM; van Sorge NM; de Melker HE; Knol MJ
    Clin Infect Dis; 2022 Jul; 74(12):2173-2180. PubMed ID: 34525199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
    Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
    Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales.
    Trotter CL; Edmunds WJ
    BMJ; 2002 Apr; 324(7341):809. PubMed ID: 11934772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
    Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
    Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States.
    Mbaeyi S; Pondo T; Blain A; Yankey D; Potts C; Cohn A; Hariri S; Shang N; MacNeil JR
    JAMA Pediatr; 2020 Sep; 174(9):843-851. PubMed ID: 32687590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France.
    de Pouvourville G; Breau-Brunel M; Loncle-Provot V; Beck E; Gaugain L; Nachbaur G; Pribil C
    Pharmacoecon Open; 2024 Jul; 8(4):539-557. PubMed ID: 38780884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction.
    Villena R; Valenzuela MT; Bastías M; Santolaya ME
    Vaccine; 2022 Jan; 40(4):666-672. PubMed ID: 34996641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.